ZNF57 Inhibitors
Chemical inhibitors of ZNF57 include a range of compounds that function by disrupting cellular processes and signaling pathways crucial for the functional activity of ZNF57. Palbociclib and PD0332991, both CDK4/6 inhibitors, arrest the cell cycle in the G1 phase. This cell cycle arrest impedes any potential involvement of ZNF57 in cell cycle-dependent transcriptional regulation by preventing progression to phases where ZNF57 might be active. Similarly, histone deacetylase inhibitors like Trichostatin A, Vorinostat, Romidepsin, Entinostat, Belinostat, and Panobinostat induce hyperacetylation of histones, leading to a relaxed chromatin conformation. This alteration can impede the ability of ZNF57 to bind to its DNA targets, as the protein may require a specific chromatin context for binding and functional activity.
Furthermore, inhibitors of EGFR such as Rociletinib, Afatinib, Erlotinib, and Gefitinib obstruct signaling pathways that ZNF57 may be a part of. By inhibiting EGFR tyrosine kinase activity, these compounds could disrupt downstream signaling cascades that ZNF57 is associated with, leading to a decrease in the functional activity of ZNF57 within these pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD0332991, also known as Palbociclib, inhibits CDK4/6 leading to cell cycle arrest at G1 phase. If ZNF57 plays a role in cell cycle-dependent transcription, its function would be inhibited as the cell cycle is arrested. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylases (HDAC), which leads to an increase in acetylated histones, typically associated with active transcription. Inhibition of HDAC can result in altered chromatin structure, potentially inhibiting ZNF57 binding to DNA. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat inhibits HDACs leading to increased histone acetylation. This can change the chromatin structure and subsequently inhibit the DNA-binding ability of ZNF57 if it targets acetylated histone-bound regions. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin is another HDAC inhibitor that could inhibit ZNF57's function by altering chromatin architecture and accessibility, potentially preventing ZNF57 from interacting with its target DNA sequences. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat selectively inhibits class I HDACs which could lead to a chromatin state that is less conducive to ZNF57 binding, thereby inhibiting its function. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat inhibits HDAC activity leading to epigenetic modulation. Changes in chromatin structure could inhibit the DNA-binding ability of ZNF57, thus inhibiting its function. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is a potent HDAC inhibitor that can lead to hyperacetylated chromatin, which may inhibit ZNF57 by altering the transcriptional landscape and its ability to bind DNA. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Afatinib irreversibly inhibits EGFR family kinases. Inhibition of these kinases could disrupt signaling pathways in which ZNF57 is involved, leading to its functional inhibition. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib selectively inhibits EGFR tyrosine kinase, which may inhibit downstream signaling pathways involving ZNF57, leading to functional inhibition of ZNF57. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an inhibitor of EGFR tyrosine kinase which could inhibit signaling pathways that involve ZNF57, causing functional inhibition of ZNF57's role within these pathways. | ||||||